S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
NASDAQ:DNLI

Denali Therapeutics (DNLI) Stock Forecast, Price & News

$24.72
+0.95 (+4.00%)
(As of 05/20/2022 12:00 AM ET)
Add
Compare
Today's Range
$23.06
$24.85
50-Day Range
$20.88
$35.19
52-Week Range
$20.24
$79.70
Volume
443,288 shs
Average Volume
660,375 shs
Market Capitalization
$3.04 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.9
30 days | 90 days | 365 days | Advanced Chart
Receive DNLI News and Ratings via Email

Sign-up to receive the latest news and ratings for Denali Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Denali Therapeutics logo

About Denali Therapeutics

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease. The company also develops DNL310 that is in Phase I/II clinical trials for the treatment of hunter syndrome; DNL343, which is in phase 1 clinical trial the treatment of amyotrophic lateral sclerosis (ALS); AR443820/DNL788 completed a phase I clinical trial for the treatment of ALS, multiple sclerosis (MS), and Alzheimer's disease; and SAR443122/DNL758, which is in phase II clinical trial for the treatment of cutaneous lupus erythematosus. It has collaboration agreement with Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene; and a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG. to develop antisense therapies in the field of neurodegenerative diseases. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:DNLI
Fax
N/A
Employees
380
Year Founded
N/A

Sales & Book Value

Annual Sales
$48.66 million
Book Value
$7.47 per share

Profitability

Net Income
$-290.58 million
Net Margins
-344.79%
Pretax Margin
-345.49%

Debt

Price-To-Earnings

Miscellaneous

Free Float
102,047,000
Market Cap
$3.04 billion
Optionable
Optionable

Company Calendar

Last Earnings
5/05/2022
Today
5/22/2022
Next Earnings (Estimated)
8/03/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

2.37 out of 5 stars

Medical Sector

213th out of 1,416 stocks

Biological Products, Except Diagnostic Industry

32nd out of 210 stocks

Analyst Opinion: 3.5Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.6 5 -4 -3 -2 -1 -













Denali Therapeutics (NASDAQ:DNLI) Frequently Asked Questions

Is Denali Therapeutics a buy right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Denali Therapeutics in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Denali Therapeutics stock.
View analyst ratings for Denali Therapeutics
or view top-rated stocks.

When is Denali Therapeutics' next earnings date?

Denali Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 3rd 2022.
View our earnings forecast for Denali Therapeutics
.

How were Denali Therapeutics' earnings last quarter?

Denali Therapeutics Inc. (NASDAQ:DNLI) released its quarterly earnings results on Thursday, May, 5th. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.47) by $0.06. The company had revenue of $42.10 million for the quarter, compared to analysts' expectations of $33.32 million. Denali Therapeutics had a negative trailing twelve-month return on equity of 28.83% and a negative net margin of 344.79%. The business's quarterly revenue was up 432.9% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.58) EPS.
View Denali Therapeutics' earnings history
.

What price target have analysts set for DNLI?

7 brokerages have issued 1-year price objectives for Denali Therapeutics' stock. Their forecasts range from $48.00 to $111.00. On average, they anticipate Denali Therapeutics' share price to reach $88.00 in the next year. This suggests a possible upside of 256.0% from the stock's current price.
View analysts' price targets for Denali Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Denali Therapeutics' key executives?
Denali Therapeutics' management team includes the following people:
  • Dr. Ryan J. Watts Ph.D., Co-Founder, Pres, CEO & Director (Age 46, Pay $1.13M)
  • Dr. Alexander O. Schuth M.D., Co-Founder, COO & Sec. (Age 49, Pay $755.81k) (LinkedIn Profile)
  • Dr. Marc Tessier-Lavigne Ph.D., Co-Founder, Chairman of Scientific Advisory Board & Independent Director (Age 62, Pay $58.14k)
  • Mr. Steve Edward Krognes, CFO & Treasurer (Age 54, Pay $813.44k)
  • Dr. Carole Ho M.D., Chief Medical Officer & Head of Devel. (Age 49, Pay $769.39k)
  • Mr. Tyler M. Nielsen, VP of Corp. Fin. (Age 44)
  • Dr. Dana Andersen, Chief Technical and Manufacturing Officer
  • Mr. Joe Lewcock, Chief Scientific Officer
  • Dr. Laura Hansen, VP of Investor Relations
  • Mr. Chris Walsh, Associate Gen. Counsel
What is Ryan Watts' approval rating as Denali Therapeutics' CEO?

1 employees have rated Denali Therapeutics CEO Ryan Watts on Glassdoor.com. Ryan Watts has an approval rating of 100% among Denali Therapeutics' employees. This puts Ryan Watts in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Denali Therapeutics own?
When did Denali Therapeutics IPO?

(DNLI) raised $149 million in an initial public offering (IPO) on Friday, December 8th 2017. The company issued 8,300,000 shares at a price of $17.00-$19.00 per share. Goldman Sachs, Morgan Stanley and J.P. Morgan served as the underwriters for the IPO and Evercore ISI was co-manager.

What is Denali Therapeutics' stock symbol?

Denali Therapeutics trades on the NASDAQ under the ticker symbol "DNLI."

Who are Denali Therapeutics' major shareholders?

Denali Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Baillie Gifford & Co. (12.19%), BlackRock Inc. (6.66%), Vanguard Group Inc. (6.60%), State Street Corp (3.11%), Gilder Gagnon Howe & Co. LLC (2.13%) and Bank of New York Mellon Corp (1.31%). Company insiders that own Denali Therapeutics stock include Alexander O Schuth, Alexander O Schuth, Carole Ho, David P Schenkein, Douglas K Bratton, Marc Tessier-Lavigne, Ryan J Watts, Ryan J Watts, Steve E Krognes, Steve E Krognes, Vicki L Sato and Vicki L Sato.
View institutional ownership trends for Denali Therapeutics
.

Which institutional investors are selling Denali Therapeutics stock?

DNLI stock was sold by a variety of institutional investors in the last quarter, including Gilder Gagnon Howe & Co. LLC, Prudential Financial Inc., Citigroup Inc., Baillie Gifford & Co., Integral Health Asset Management LLC, AIA Group Ltd, Principal Financial Group Inc., and UBS Group AG. Company insiders that have sold Denali Therapeutics company stock in the last year include Alexander O Schuth, Carole Ho, Marc Tessier-Lavigne, Ryan J Watts, Steve E Krognes, and Vicki L Sato.
View insider buying and selling activity for Denali Therapeutics
or view top insider-selling stocks.

Which institutional investors are buying Denali Therapeutics stock?

DNLI stock was acquired by a variety of institutional investors in the last quarter, including State Street Corp, Bank of New York Mellon Corp, Woodline Partners LP, Federated Hermes Inc., Dimensional Fund Advisors LP, BlackRock Inc., The Manufacturers Life Insurance Company , and Renaissance Technologies LLC.
View insider buying and selling activity for Denali Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Denali Therapeutics?

Shares of DNLI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Denali Therapeutics' stock price today?

One share of DNLI stock can currently be purchased for approximately $24.72.

How much money does Denali Therapeutics make?

Denali Therapeutics has a market capitalization of $3.04 billion and generates $48.66 million in revenue each year. The company earns $-290.58 million in net income (profit) each year or ($2.34) on an earnings per share basis.

How many employees does Denali Therapeutics have?

Denali Therapeutics employs 380 workers across the globe.

What is Denali Therapeutics' official website?

The official website for Denali Therapeutics is www.denalitherapeutics.com.

How can I contact Denali Therapeutics?

Denali Therapeutics' mailing address is 161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at (615) 866-8548 or via email at [email protected].

This page was last updated on 5/22/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.